Terry Opgenorth

NeoTREX, Inc. provides healthcare services. The non-profit company is based in Fort Collins, CO.

The Colorado Institute For Drug Device & Diagnostic Development provides health maintenance services. The American company was founded by Richard C. Duke.

KromaTid, Inc. provides products and services for mutation detection and disease diagnosis. Its services include high resolution screening of individual genes to the entire genome, sequence, location and orientation from a single assay, cost effective discovery of inversions and translocations, rapid assay development and data delivery. The company was founded by Andrew F. Ray, Susan M. Bailey, Michael Cornforth, Edwin Goodwin, and Joel S. Bedford in 2007 and is headquartered in Longmont, CO.

Sparta Healthcare Acquisition Corp. is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on January 12, 2021 and is headquartered in Fort Collins, CO.

PhotonPharma, Inc. is a company that is developing a personalized therapeutic cancer vaccine called Innocell. The company is based in Fort Collins, CO, at the Research Innovation Center of Colorado State University. The vaccine is designed using autologous tumor tissue and a photochemical inactivation platform that uses riboflavin and UV light to render tumor cells incapable of replication while still being able to metabolize, express proteins, present antigen, and stimulate immune recognition and response mechanisms. The company has demonstrated the ability of this technology to prevent metastatic tumor formation, reduce the growth of tumors, and stimulate cellular immune response pathways in preclinical development animal models. The company was founded in 2018 by Raymond Goodrich, and the CEO is Alan S. Rudolph.

Cetya Therapeutics, Inc. engages in the commercialization of histone deacetylase inhibitors based on largazole. Its histone deacetylase inhibitors analog has bifunctional modifications and the potential to target specific cell types or tumors. The company was founded by John Pilon in 2012 and is headquartered in Fort Collins, Co.